Document is current
Any future updates will be listed below
-
Authors
Spartalis, Christoph https://orcid.org/0009-0004-1735-8372
Ullrich, Marlies
Winkler, Silvia
Leisser, Christoph
Ruiss, Manuel
Pilwachs, Caroline
Findl, Oliver
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct07390253 at ClinicalTrials.govDocuments that mention this clinical trial
Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden
https://doi.org/10.1007/s40123-026-01394-1
-
Funding
Funding for this research was provided by:
Bayer
- License Information
-
More Information
Article History
Received: 7 March 2026
Accepted: 24 April 2026
First Online: 19 May 2026
Declarations
:
: Christoph Spartalis reports consultancy for Bayer. Oliver Findl is a scientific advisor to Carl Zeiss Meditec AG, Croma, and Johnson & Johnson. Marlies Ullrich, Silvia Winkler, Christoph Leisser, Manuel Ruiss, and Caroline Pilwachs declare that they have no competing interests.
: The study was approved by the Ethics Committee of the City of Vienna (EK 24-105-0824, NCT07390253) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. No identifying participant information is included in this manuscript.
: The authors thank the patients who participated in this study for their contribution to clinical research.
: Patients were not involved in the design, conduct, reporting, or dissemination of this research.
